You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

NATESTO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Natesto, and what generic alternatives are available?

Natesto is a drug marketed by Acerus and is included in one NDA. There are five patents protecting this drug.

This drug has thirty-one patent family members in twenty-two countries.

The generic ingredient in NATESTO is testosterone. There are sixty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Natesto

A generic version of NATESTO was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NATESTO?
  • What are the global sales for NATESTO?
  • What is Average Wholesale Price for NATESTO?
Summary for NATESTO
International Patents:31
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 73
Clinical Trials: 9
Patent Applications: 4,308
Drug Prices: Drug price information for NATESTO
What excipients (inactive ingredients) are in NATESTO?NATESTO excipients list
DailyMed Link:NATESTO at DailyMed
Drug patent expirations by year for NATESTO
Drug Prices for NATESTO

See drug prices for NATESTO

Recent Clinical Trials for NATESTO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Southern California College of Optometry at Marshall B. Ketchum UniversityPhase 2
University of FloridaPhase 4
Acerus PharmaceuticalPhase 4

See all NATESTO clinical trials

Pharmacology for NATESTO
Drug ClassAndrogen
Mechanism of ActionAndrogen Receptor Agonists

US Patents and Regulatory Information for NATESTO

NATESTO is protected by five US patents.

Patents protecting NATESTO


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

Controlled release delivery system for nasal applications
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Controlled release delivery system for nasal applications and methods of treatment
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Controlled release delivery system for nasal applications and method of treatment
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.

Controlled release delivery system for nasal applications
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NATESTO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 ⤷  Sign Up ⤷  Sign Up
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 ⤷  Sign Up ⤷  Sign Up
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for NATESTO

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Warner Chilcott UK Ltd. Intrinsa testosterone EMEA/H/C/000634
Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
Warner ChilcottĀ  Deutschland GmbH Livensa testosterone EMEA/H/C/000630
Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for NATESTO

See the table below for patents covering NATESTO around the world.

Country Patent Number Title Estimated Expiration
Austria 319426 ⤷  Sign Up
Canada 2541498 SYSTEME D'ADMINISTRATION A LIBERATION CONTROLEE POUR APPLICATIONS NASALES (CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS) ⤷  Sign Up
Taiwan I350176 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.